A Phase 1b/2 Trial to Evaluate the Safety and Efficacy of Radium-223 Dichloride (BAY88-8223) in Combination With Bortezomib and Dexamethasone in Early Relapsed Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Radium 223 chloride (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bayer
- 23 Mar 2017 Status changed from not yet recruiting to recruiting.
- 17 Feb 2017 Planned initiation date changed from 1 Jan 2017 to 1 Feb 2017.
- 10 Jan 2017 Planned End Date changed from 1 Jan 2021 to 1 May 2022.